AstraZeneca

News

AZ, Daiichi eye December verdict for TROP2 ADC

The FDA has started a review of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan as a therapy for lung cancer, the second drug in their antibody-drug conjugate (ADC

News

Tagrisso-chemo cleared in US as 1st-line lung cancer therapy

AstraZeneca’s Tagrisso can be used alongside chemotherapy as a frontline therapy for EGFR-positive non-small cell lung cancer (NSCLC), according to the FDA, consolidating

News

FDA starts swift review of tumour-agnostic use of Enhertu

AstraZeneca and Daiichi Sankyo’s Enhertu could become the first therapy approved by the FDA for use in any HER2-positive cancer, regardless of its location in the body.

News

AZ may get government aid for UK vaccines facility; report

The UK government is reportedly considering a financial aid package to encourage AstraZeneca to invest in an expansion of its vaccines manufacturing facility in Speke, nea

News

Trial data raises questions about Imfinzi in liver cancer

AstraZeneca is trying to blaze a new trial for immunotherapy in liver cancer with its EMERALD-1 trial, but the jury is out on its prospects.

News

AZ bags first approval for PNH therapy danicopan, in Japan

AstraZeneca has claimed its first regulatory approval for oral Factor D inhibitor danicopan, getting a green light in Japan for the drug as Voydeya for the treatment of pa

AZ, Daiichi eye December verdict for TROP2 ADC

Tagrisso-chemo cleared in US as 1st-line lung cancer therapy

FDA starts swift review of tumour-agnostic use of Enhertu

AZ may get government aid for UK vaccines facility; report

Trial data raises questions about Imfinzi in liver cancer

AZ bags first approval for PNH therapy danicopan, in Japan

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

AstraZeneca

Editor's Picks